Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neoplasms 1Pancreatic Fistula 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Hypoglycemia 1Gastro-enteropancreatic neuroendocrine tumor 1Dumping Syndrome 1Acromegaly 1

Interventions

Dexmedetomidine 3Cabergoline 3pegvisomant 1pasireotide 1lanreotide 1Trimethoprim 1Sulfamethoxazole 1Sodium Chloride 1Sevoflurane 1Saline Solution 1Propofol 1Prednisone 1Octreotide 1Ibuprofen 1Hydrocortisone 1Hormone Replacement Therapy 1Cefdinir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Pituitary Neoplasms × pasireotide × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡